Ackermans & Van Haaren – link to home page Ackermans & Van Haaren – link to home page
Banner image

OncoDNA

Oncodna

OncoDNA supports cancer specialists by providing comprehensive characterization of a patient’s cancer.

Included in the AvH investment portfolio since 2016.

Visit website Back > Life sciences portfolio

9.54 %

Beneficial interest AvH

Press releases - Growth capital

View All
Growth Capital

Biotalys: Industry Leaders Christine Berwaerts and Ioana Tudor Join Biotalys’ Board as Independent Directors

Read more
Growth Capital

Biotalys Secures Product Registration in California for EVOCA®, Strengthening Regulatory Pathway for Its Lead Asset EVOCA NG

Read more

Related participations

Confo Therapeutics

Growth Capital

Confo Therapeutics

La mission de Confo est de développer de nouveaux modulateurs de GPCR pour les patients atteints de maladies graves, en mettant actuellement l'accent sur les maladies rares, la douleur périphérique et l'obésité.

Read more
MRM Health

Growth Capital

MRM Health

MRM Health, established in the Ghent biotech cluster, develops innovative human microbiome-based medicines.

Read more
Vico Therapeutics

Growth Capital

Vico Therapeutics

Vico Therapeutics is a Dutch biotech company developing novel Antisense-Oligonucleotide (ASO) therapies for rare diseases.

Read more